Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients

Abstract

Background

Targeted therapy with tyrosine kinase inhibitors with anti-vascular endothelial growth factor activity improves survival of cancer patients. Cardiovascular complications are critical and it is unknown whether these require specific treatment strategies. We aimed to clarify the associated risk of cardiovascular adverse events in patients treated with tyrosine kinase inhibitors.

Design

The design of this study was a meta-analysis of randomised controlled trials.

Methods

We searched PubMed, Cochrane, EMBASE and Web of Science databases for randomised controlled trials published until January 2017 that assessed patients with different types of cancer treated with or without tyrosine kinase inhibitors in addition to standard chemotherapy.

Results

A total of 29,252 patients from 71 randomised controlled trials were included. Tyrosine kinase inhibitor treatment was associated with a higher cardiac ischaemia relative risk (relative risk = 1.69; 95% confidence interval: 1.12–2.57; p = 0.01), with the highest risks observed for sorafenib and patients with renal cancer. Risk of thrombocytopaenia (relative risk = 2.2; 95% confidence interval: 1.73–2.79; p < 0.001) was highest for regorafenib and patients with breast cancer. Left ventricular systolic dysfunction was increased after tyrosine kinase inhibitor therapy (relative risk = 2.53; 95% confidence interval:1.79 – 3.57; p < 0.001), with the highest risks reported for sunitinib and hepatocellular cancer. QT corrected interval prolongation (relative risk = 6.25; 95% confidence interval: 3.44–11.38; p < 0.001) and arterial hypertension (relative risk = 3.78; 95% confidence interval: 3.15-4.54; p < 0.001) were reported. The relative risks of arterial adverse events, cerebral ischaemia, venous adverse events and pulmonary embolism were similar across groups.

Conclusion

Tyrosine kinase inhibitors increase the risk of severe cardiovascular and particularly thrombotic adverse events. Specific treatment regimens when prescribing tyrosine kinase inhibitor therapies appear desirable.

Keywords

Tyrosine kinase inhibitors cardiovascular adverse events meta-analysis

Get full access to this article

View all access options for this article.

References

Siegel

Miller

Jemal

. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7–30.

Zamorano

Lancellotti

Rodriguez Munoz

et al.

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 2768–2801.

Jayson

Kerbel

Ellis

et al.

Antiangiogenic therapy in oncology: Current status and future directions. Lancet 2016; 388: 518–529.

Croce

Steensma

et al.

Vascular and metabolic implications of novel targeted cancer therapies: Focus on kinase inhibitors. J Am Coll Cardiol 2015; 66: 1160–1178.

Liu

Ding

Liu

et al.

Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget 2016; 7: 67661–67673.

Choueiri

Schutz

et al.

Risk of arterial thromboembolic events with sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. J Clin Oncol 2010; 28: 2280–2285.

Barnes

Chan

et al.

The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Lung Cancer 2016; 102: 21–27.

Wen

Xiao

Luo

et al.

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis. Oncotarget 2017; 8(12): 20441–20451.

Zhang

Leung

et al.

Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: A systematic review and meta-analysis. J Hematol Oncol 2016; 9: 111–111.

10.

Zhang

Zhao

. Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: A meta-analysis and systematic review. Onco Targets Ther 2016; 9: 3695–3704.

11.

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org.

12.

Liberati

Altman

Tetzlaff

et al.

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009; 339: b2700–b2700.

13.

Totzeck

Mincu

Rassaf

. Cardiovascular adverse events in patients with cancer treated with bevacizumab: A meta-analysis of more than 20 000 patients. J Am Heart Assoc 2017; 6(8): doi: 10.1161/JAHA.117.006278.

14.

Belani CP, Yamamoto N, Bondarenko IM, et al. Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC Cancer. 2014; 14: 290. doi: 10.1186/1471-2407-14-290.

15.

Ioka

Okusaka

Ohkawa

et al.

Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: Subgroup analyses by region, including Japan, from the global randomized Phase III trial. Jpn J Clin Oncol 2015; 45: 439–448.

16.

Kang

Yau

Park

et al.

Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol 2015; 26: 2457–2463.

17.

Kindler

Ioka

Richel

et al.

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomised phase 3 study. Lancet Oncol 2011; 12: 256–262.

18.

Rini

Melichar

Ueda

et al.

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: A randomised double-blind phase 2 trial. Lancet Oncol 2013; 14: 1233–1242.

19.

Rugo

Stopeck

Joy

et al.

Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 2011; 29: 2459–2465.

20.

Spano

Chodkiewicz

Maurel

et al.

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: An open-label randomised phase II study. Lancet 2008; 371: 2101–2108.

21.

Schlumberger

Tahara

Wirth

et al.

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015; 372: 621–630.

22.

Motzer

Hutson

Glen

et al.

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015; 16: 1473–1482.

23.

du Bois

Kristensen

Ray-Coquard

et al.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2016; 17: 78–89.

24.

Hanna

Kaiser

Sullivan

et al.

Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. Lung Cancer 2016; 102: 65–73.

25.

Ledermann

Hackshaw

Kaye

et al.

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011; 29: 3798–3804.

26.

Reck

Kaiser

Mellemgaard

et al.

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15: 143–155.

27.

Sternberg

Davis

Mardiak

et al.

Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061–1068.

28.

van der Graaf

Blay

Chawla

et al.

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879–1886.

29.

Mir

Cropet

Toulmonde

et al.

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): A randomised, multicentre, open-label phase 2 trial. Lancet Oncol 2016; 17: 632–641.

30.

du Bois

Floquet

Kim

et al.

Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 2014; 32: 3374–3382.

31.

O'Brien

Gaafar

Hasan

et al.

Maintenance pazopanib versus placebo in non-small cell lung cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). Eur J Cancer 2015; 51: 1511–1528.

32.

Pignata

Lorusso

Scambia

et al.

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): A randomised, open-label, phase 2 trial. Lancet Oncol 2015; 16: 561–568.

33.

Demetri

Reichardt

Kang

et al.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 295–302.

34.

Grothey

Van Cutsem

Sobrero

et al.

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303–312.

35.

Pavlakis

Sjoquist

Martin

et al.

Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II trial. J Clin Oncol 2016; 34: 2728–2735.

36.

Bruix

Qin

Merle

et al.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 56–66.

37.

Mir

Brodowicz

Italiano

et al.

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2016; 17: 1732–1742.

38.

Qin

et al.

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16: 619–629.

39.

Abou-Alfa

Johnson

Knox

et al.

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial. JAMA 2010; 304: 2154–2160.

40.

Baselga

Costa

Gomez

et al.

A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): Study protocol for a randomized controlled trial. Trials 2013; 14: 228–228.

41.

Brose

Nutting

Jarzab

et al.

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet 2014; 384: 319–328.

42.

Bruix

Takayama

Mazzaferro

et al.

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16: 1344–1354.

43.

Cheng

Kang

Chen

et al.

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25–34.

44.

Escudier

Eisen

Stadler

et al.

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312–338.

45.

Flaherty

Lee

Zhao

et al.

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol 2013; 31: 373–379.

46.

Goncalves

Gilabert

Francois

et al.

BAYPAN study: A double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 2012; 23: 2799–2805.

47.

Gradishar

Kaklamani

Sahoo

et al.

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer 2013; 49: 312–322.

48.

Hauschild

Agarwala

Trefzer

et al.

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009; 27: 2823–2830.

49.

Hainsworth

Thompson

Bismayer

et al.

Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute. Cancer Med 2015; 4: 673–681.

50.

Herzog

Scambia

Kim

et al.

A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol Oncol 2013; 130: 25–30.

51.

Krege

Rexer

vom Dorp

et al.

Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05). BJU Int 2014; 113: 429–436.

52.

Llovet

Ricci

Mazzaferro

et al.

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–390.

53.

McDermott

Sosman

Gonzalez

et al.

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 Study Group. J Clin Oncol 2008; 26: 2178–2185.

54.

Negrier

Jager

Porta

et al.

Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol 2010; 27: 899–906.

55.

Paz-Ares

Biesma

Heigener

et al.

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012; 30: 3084–3092.

56.

Scagliotti

Novello

von Pawel

et al.

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 1835–1842.

57.

Schwartzberg

Tauer

Hermann

et al.

Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res 2013; 19: 2745–2754.

58.

Tabernero

Garcia-Carbonero

Cassidy

et al.

Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: The RESPECT trial. Clin Cancer Res 2013; 19: 2541–2550.

59.

Haas

Manola

Uzzo

et al.

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016; 387: 2008–2016.

60.

Bergh

Bondarenko

Lichinitser

et al.

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study. J Clin Oncol 2012; 30: 921–929.

61.

Carrato

Swieboda-Sadlej

Staszewska-Skurczynska

et al.

Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: A randomized, phase III trial. J Clin Oncol 2013; 31: 1341–1347.

62.

Crown

Dieras

Staroslawska

et al.

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 2013; 31: 2870–2878.

63.

Demetri

van Oosterom

Garrett

et al.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006; 368: 1329–1338.

64.

Heist

Wang

Hodgson

et al.

CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2014; 9: 214–221.

65.

Michaelson

Oudard

et al.

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 2014; 32: 76–82.

66.

Moehler

Gepfner-Tuma

Maderer

et al.

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: A randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC Cancer 2016; 16: 699–699.

67.

Raymond

Dahan

Raoul

et al.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501–513.

68.

Reni

Cereda

Milella

et al.

Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial. Eur J Cancer 2013; 49: 3609–3615.

69.

Wildiers

Fontaine

Vuylsteke

et al.

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010; 123: 463–469.

70.

Lee

et al.

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 2012; 106: 1469–1474.

71.

Motzer

Hutson

Tomczak

et al.

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584–3590.

72.

Aisner

Manola

Dakhil

et al.

Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: A randomized phase 2 PrECOG study (PrE0501). J Thorac Oncol 2013; 8: 1075–1083.

73.

Ahn

Lee

Sun

et al.

A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. Lung Cancer 2013; 82: 455–460.

74.

Arnold

Seymour

Smylie

et al.

Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007; 25: 4278–4284.

75.

de Boer

Arrieta

Yang

et al.

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: A randomized, double-blind phase III trial. J Clin Oncol 2011; 29: 1067–1074.

76.

Coleman

Moon

Sood

et al.

Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 2014; 50: 1638–1648.

77.

Herbst

Sun

Eberhardt

et al.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial. Lancet Oncol 2010; 11: 619–626.

78.

Heymach

Johnson

Prager

et al.

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007; 25: 4270–4277.

79.

Heymach

Paz-Ares

De Braud

et al.

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 5407–5415.

80.

Horti

Widmark

Stenzl

et al.

A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm 2009; 24: 175–180.

81.

Hsu

Yang

Huo

et al.

Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study. J Hepatol 2012; 56: 1097–1103.

82.

Leboulleux

Bastholt

Krause

et al.

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial. Lancet Oncol 2012; 13: 897–905.

83.

Lee

Hirsh

Park

et al.

Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012; 30: 1114–1121.

84.

Sanborn

Patel

Masters

et al.

A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113. Cancer 2017; 123: 303–311.

85.

Wells

Jr Robinson

Gagel

et al.

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134–141.

86.

Kang

Yau

Park

et al.

Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol 2015; 26: 2457–2463.

87.

Belani

Yamamoto

Bondarenko

et al.

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC Cancer 2014; 14: 290–290.

88.

Wildiers

Fontaine

Vuylsteke

et al.

89.

Grothey

Van Cutsem

Sobrero

et al.

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303–312.

90.

Hauschild

Gutzmer

Ugurel

et al.

Sorafenib and pegylated interferon alpha 2b in advanced metastatic melanoma: A multicenter phase II DECOG trial. Melanoma Res 2010; 20: e33–e33.

91.

Totzeck

Hendgen-Cotta

Luedike

et al.

Nitrite regulates hypoxic vasodilation via myoglobin-dependent nitric oxide generation. Circulation 2012; 126: 325–334.

92.

Verheul

Pinedo

. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7: 475–485.

93.

Schraermeyer

Julien

. Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye. Graefes Arch Clin Exp Ophthalmol 2012; 250: 1303–1313.

94.

Bellinger

Arteaga

Force

et al.

Cardio-oncology: How new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation 2015; 132: 2248–2258.

95.

Shen

Tang

et al.

Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis. Crit Rev Oncol Hematol 2014; 92: 71–82.

96.

Abdel-Qadir

Ethier

Lee

et al.

Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev 2017; 53: 120–127.

97.

Ranpura

Hapani

Chuang

et al.

Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncol 2010; 49: 287–297.

98.

Funakoshi

Latif

Galsky

. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: A systematic review and meta-analysis of randomized controlled trials. Cancer Treat Rev 2014; 40: 636–647.

99.

Schutz

Richards

et al.

Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012; 30: 871–877.

100.

Abdel-Rahman

Elhalawani

. Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: A comparative meta-analysis. Future Oncol 2015; 11: 1109–1122.

101.

Massey

Okman

Wilkerson

et al.

Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: A meta-analysis and review of the literature. Support Care Cancer 2015; 23: 1827–1835.

102.

Teo

Chan

. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis. Cancer Treat Rev 2013; 39: 199–206.

103.

Ghatalia

Kaymakcalan

et al.

QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2015; 112: 296–305.

104.

Klein Hesselink

Steenvoorden

Kapiteijn

et al.

Therapy of endocrine disease: Response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: A systematic review and meta-analysis. Eur J Endocrinol 2015; 172: R215–R225.

105.

Lyman

Khorana

Kuderer

et al.

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31: 2189–2204.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.91 MB

0.48 MB